Computer System Validation (CSV / CSA)
TalkFDA Knowledge Hub from Industry Experts
What is the difference between CSV and CSA?
Computer System Validation (CSV) and Computer Software Assurance (CSA) are not competing frameworks. CSV remains the foundational expectation across GxP environments, while CSA represents FDA’s modernization of how assurance is executed, particularly for production and quality system software. The distinction matters because regulators are no longer judging validation strength by documentation volume, but by how well risk to product quality, patient safety, and data integrity is understood and controlled.
Point-by-Point Comparison
1. Purpose
CSV is designed to demonstrate that a computerized system is fit for its intended use across its lifecycle. It focuses on establishing and maintaining control, ensuring the system consistently supports GMP activities, and protecting data integrity.
CSA narrows that focus to confidence in software functions that directly impact production or the quality system. The intent is not to validate less, but to eliminate effort that does not meaningfully reduce risk.
Operationally:
- CSV asks: “Have we proven the system meets all requirements?”
- CSA asks: “Have we focused assurance on what could actually fail and harm quality or safety?”
2. Regulatory Basis
CSV is anchored in long-standing FDA expectations, including 21 CFR Part 11, Part 820, and the General Principles of Software Validation. It is reinforced globally through MHRA, EMA, and WHO data integrity and computerized system expectations.
CSA is introduced through FDA guidance specific to production and quality system software. It does not replace CSV or global validation frameworks. Instead, it interprets them through a risk-based lens.
Key reality:
- Regulators outside FDA have not replaced CSV with CSA
- Inspection expectations still align with lifecycle control, traceability, and data integrity
- CSA is an evolution in approach, not a regulatory exemption
3. Documentation Expectations
CSV typically drives heavy documentation:
- Detailed URS, FS, DS
- Full traceability matrices
- Pre-approved validation protocols
- Step-by-step executed test scripts
- Formal deviation logs and summary reports
CSA still requires objective evidence, but documentation is scaled to risk and method of assurance.
What changes in practice:
- Low-risk functions may only require concise evidence of verification
- High-risk functions still demand structured testing and clear traceability
- Documentation must justify why the level of testing is sufficient, not just show that testing occurred
Common inspection failure under CSA:
- Teams reduce documentation volume but fail to document risk rationale
- Missing justification for why unscripted testing was acceptable
- Over-reliance on “light documentation” without evidence of critical thinking
4. Testing Philosophy
CSV relies heavily on scripted testing:
- Predefined test steps
- Expected results documented in advance
- Execution recorded exactly as written
This often leads to:
- Mechanical test execution
- Limited ability to detect unexpected system behavior
- High effort spent on low-risk scenarios
CSA introduces a mixed testing model:
- Scripted testing for high-risk functions
- Unscripted or exploratory testing for lower-risk or well-understood functionality
- Targeted testing based on failure impact
Unscripted testing is a significant shift:
- Testers are not constrained by predefined steps
- Real-world usage scenarios are explored dynamically
- Defects related to usability, configuration, and edge cases are more likely to surface
Where companies fail:
- Treating unscripted testing as informal or undocumented
- Not recording what was actually tested, by whom, and with what outcome
- Inability to demonstrate repeatability or coverage during inspection
5. Risk Profile and Assurance Focus
CSV often applies a uniform validation approach regardless of risk, resulting in:
- Over-validation of low-risk features such as UI formatting or non-critical workflows
- Excessive testing of vendor-standard functionality
CSA explicitly prioritizes risk:
- High process risk functions receive rigorous assurance
- Low-risk functions receive minimal but sufficient verification
- Risk is tied to impact on patient safety, product quality, and data integrity
Examples:
- A calculation impacting batch release requires strong verification and traceability
- A report layout or dashboard filter may only require basic confirmation of functionality
Inspection concern:
- Poor risk assessment leading to under-testing of critical functions
- Lack of linkage between risk classification and testing depth
6. Review Standard (What Inspectors Look For)
Under CSV, inspectors often focused on:
- Completeness of documentation
- Presence of traceability
- Execution of approved protocols
Under CSA, the focus shifts to:
- Whether risk was correctly identified and justified
- Whether assurance activities align with that risk
- Whether objective evidence supports system reliability
Typical red flags:
- Large volumes of documentation with no clear risk prioritization
- Reduced documentation with no supporting rationale
- Inconsistent application of testing methods across similar risk levels
7. Operational Implications
CSV drives:
- Longer validation cycles
- Significant effort in script authoring and execution
- Duplication of supplier testing
- Heavy reliance on documentation to demonstrate compliance
CSA enables:
- Reduced validation timelines for low-risk systems
- Greater use of supplier documentation and testing evidence
- Less redundant testing of standard or configurable software
- Shift toward lifecycle assurance including ongoing monitoring
Key operational changes:
- Validation teams must perform stronger upfront risk assessments
- Testers need higher skill levels to execute exploratory testing effectively
- Quality units must review rationale, not just documents
Where Companies Confuse CSV and CSA
Common misunderstandings create compliance risk:
- Assuming CSA eliminates validation documentation, leading to missing or insufficient evidence during inspection
- Replacing all scripted testing with unscripted testing without risk justification
- Reducing validation deliverables without documenting risk assessments or decision logic
- Failing to link system functions to process risk, resulting in misaligned assurance effort
- Over-relying on supplier documentation without verifying applicability to intended use
- Treating CSA as optional rather than as an FDA-endorsed expectation for risk-based assurance
These failures often result in observations tied to data integrity, inadequate validation, or lack of control over computerized systems.
Decision Takeaway
The correct approach is not choosing CSV or CSA. It is applying CSV principles through CSA methods.
Use traditional CSV rigor when:
- System functions directly impact product quality, batch release, or patient safety
- Custom development or complex integrations are involved
- Data integrity risks are high and require strict controls
Apply CSA principles when:
- Functions are low risk or well understood
- Software is configurable, not custom-built
- Supplier validation evidence is available and relevant
- Testing can be optimized without increasing risk
Final reality:
- CSV defines what must be achieved (validated state, fitness for use, data integrity)
- CSA defines how to achieve it efficiently (risk-based assurance, flexible testing, right-sized documentation)
Organizations that succeed under CSA do not do less validation. They do more defensible validation with clearer rationale, better risk alignment, and stronger evidence of control.
How is a validation lifecycle executed for GxP systems?
A GxP computerized system validation lifecycle is executed as a controlled, risk-driven process that spans from initial definition through ongoing operation. It aligns with FDA lifecycle expectations, GAMP 5 principles, and current CSA thinking, where validation is not a one-time event but continuous assurance that the system remains fit for intended use and protects product quality, patient safety, and data integrity.
1. Define Intended Use and Scope
What is done:
The system’s intended use is formally defined at a functional level, including which features impact GxP processes, electronic records, or regulatory decisions. Scope includes interfaces, data flows, and whether the system is direct or indirect impact.
The system’s intended use is formally defined at a functional level, including which features impact GxP processes, electronic records, or regulatory decisions. Scope includes interfaces, data flows, and whether the system is direct or indirect impact.
Who does it:
Business process owners with Quality and IT validation leads.
What commonly goes wrong:
- Intended use written as a vague business description without linking to GxP impact, leading to over- or under-validation
- Failure to isolate high-risk functions such as audit trails, calculations, or batch release decisions
- Mixed-use systems not decomposed into GxP and non-GxP functions, resulting in inefficient validation scope
2. Develop the Validation Plan
What is done:
A validation plan (or VMP-level document) defines lifecycle controls including deliverables, responsibilities, acceptance criteria, testing strategy, deviation handling, and change control integration.
A validation plan (or VMP-level document) defines lifecycle controls including deliverables, responsibilities, acceptance criteria, testing strategy, deviation handling, and change control integration.
Who does it:
Validation lead with Quality oversight and project stakeholders.
What commonly goes wrong:
- Generic plans reused without aligning to system complexity or risk
- Missing definition of how supplier documentation will be leveraged
- No clear strategy for handling deviations or post-go-live changes
3. Capture Requirements and Establish Traceability
What is done:
User requirements, functional requirements, data integrity controls, security roles, and regulatory expectations (e.g., 21 CFR Part 11, Annex 11) are documented and linked through a traceability matrix to design and test evidence.
Who does it:
Business SMEs define user requirements, IT/configuration teams define functional aspects, QA ensures traceability.
What commonly goes wrong:
- Requirements written at too high a level to be testable
- Missing data integrity controls such as audit trails, user access, or record retention
- Traceability gaps where critical requirements are not linked to test cases, leading to inspection findings
4. Perform Risk Assessment
What is done:
A structured risk assessment evaluates impact on product quality, patient safety, and data integrity. Each function is classified by risk to determine the level of validation effort and testing rigor.
A structured risk assessment evaluates impact on product quality, patient safety, and data integrity. Each function is classified by risk to determine the level of validation effort and testing rigor.
Who does it:
Cross-functional team including QA, IT, and process owners.
What commonly goes wrong:
- Risk scoring performed mechanically without linking to actual process impact
- Over-classification of low-risk features as high risk, driving unnecessary testing
- Failure to reassess risk after configuration changes or defect discovery
5. Evaluate Suppliers and Leverage Vendor Evidence
What is done:
The supplier’s development practices, quality system maturity, and validation documentation are assessed. Vendor testing and documentation are leveraged where justified.
The supplier’s development practices, quality system maturity, and validation documentation are assessed. Vendor testing and documentation are leveraged where justified.
Who does it:
Quality and IT vendor management with validation team input.
What commonly goes wrong:
- Blind reliance on vendor documentation without assessing applicability to intended use
- No formal supplier qualification or audit trail of evaluation
- Failure to verify site-specific configurations that alter system behavior
6. Configure and Implement the System
What is done:
System configuration includes workflows, user roles, permissions, interfaces, reports, and any customizations. Configuration must be traceable to requirements.
System configuration includes workflows, user roles, permissions, interfaces, reports, and any customizations. Configuration must be traceable to requirements.
Who does it:
IT/configuration teams with business input and QA oversight.
What commonly goes wrong:
- Configuration decisions not documented or linked to requirements
- Uncontrolled changes during build phase outside formal change control
- Security roles misaligned with actual responsibilities, creating data integrity risks
7. Execute Risk-Based Testing
What is done:
Testing is performed proportional to risk, using a mix of scripted and unscripted approaches. High-risk functions receive formal, documented testing, while lower-risk areas may use exploratory verification.
Testing is performed proportional to risk, using a mix of scripted and unscripted approaches. High-risk functions receive formal, documented testing, while lower-risk areas may use exploratory verification.
Who does it:
Validation testers, often with business user participation for functional verification.
What commonly goes wrong:
- Excessive scripted testing of low-risk functions while missing critical edge cases
- Inadequate testing of high-risk areas such as audit trails, data integrity controls, and calculations
- Poor evidence quality such as missing timestamps, unclear results, or incomplete execution records
8. Manage Deviations and Defects
What is done:
All test failures and unexpected results are documented, investigated, and assessed for impact. Decisions are made to fix, retest, or accept with justification. Changes are controlled through formal change management.
All test failures and unexpected results are documented, investigated, and assessed for impact. Decisions are made to fix, retest, or accept with justification. Changes are controlled through formal change management.
Who does it:
Validation team with QA oversight and technical input.
What commonly goes wrong:
- Deviations closed without proper root cause analysis
- Informal fixes applied without change control linkage
- Acceptance of defects without documented risk justification
9. Approve Release for GxP Use
10. Maintain the Validated State
Common Execution Gaps
Practical Takeaway
What are common validation mistakes?
Validation failures in GxP computerized systems are rarely isolated errors. They follow repeatable patterns where the validation lifecycle is fragmented or poorly justified. During FDA and GMP inspections, these weaknesses surface when firms cannot demonstrate a coherent, risk-based story from intended use through ongoing control.
1. Unclear Intended Use and System Scope
A foundational mistake is failing to define what the system is actually intended to do in a GxP context.
- Systems are labeled “validated,” but teams cannot explain which functions impact product quality, patient safety, or data integrity
- GxP and non-GxP functions are not clearly separated, leading to either over-validation or missed critical controls
- Cloud or configurable systems are deployed without defining how site-specific use affects regulatory relevance
Why this is weak: Validation cannot be justified without a clear scope. Testing and controls become arbitrary.
What regulators infer: The firm does not understand the system’s regulatory impact, which undermines all downstream validation decisions.
2. Weak, Non-Testable Requirements
Requirements frequently exist but are not written in a way that supports verification.
- Business needs are documented as broad statements instead of specific, testable system behaviors
- Requirements lack acceptance criteria, making it unclear what constitutes a pass or fail
- Critical workflows such as audit trails, access control, and data retention are vaguely defined or omitted
Why this is weak: If requirements cannot be tested, there is no objective basis for validation.
What regulators infer: The system may not have been validated against actual regulatory risks, especially under 21 CFR Part 11 expectations for electronic records and controls.
3. Broken Traceability Across the Lifecycle
Traceability gaps are one of the most cited inspection findings.
- No clear linkage between user requirements, functional specifications, risk assessments, test cases, and results
- Deviations and defect resolutions are not tied back to specific requirements
- Approval records exist but are not connected to what was actually verified
Why this is weak: Without end-to-end traceability, coverage cannot be demonstrated.
What regulators infer: The firm cannot prove that critical requirements were tested or that failures were properly resolved.
4. Misapplied Risk-Based Testing
Firms often claim a risk-based approach but fail in execution.
- Low-risk features receive extensive scripted testing, while high-risk functions receive minimal or informal verification
- No documented rationale explaining why certain tests were selected or omitted
- Critical areas such as data integrity controls, calculations, or interfaces are under-tested
Why this is weak: Testing effort is not aligned with actual risk, defeating the purpose of risk-based validation under modern guidance such as CSA principles.
What regulators infer: The validation strategy is mechanical rather than risk-driven, increasing the likelihood that critical failures were missed.
5. Inadequate Supplier Assessment and Oversight
Reliance on vendors is common, but oversight is often superficial.
- Vendor validation packages are accepted without evaluating their relevance to the site’s configuration and use
- Responsibilities for backup, security, audit trails, and data ownership are not clearly defined in SaaS or cloud systems
- No formal supplier qualification or periodic reassessment
Why this is weak: Vendor documentation does not replace site responsibility for ensuring fitness for intended use.
What regulators infer: The firm has outsourced validation responsibility without maintaining control, a direct compliance risk under GMP expectations.
6. Weak or Missing Change Control After Go-Live
Validation is treated as a one-time event instead of a lifecycle process.
- Software patches, upgrades, and configuration changes are implemented under IT processes without validation impact assessment
- Interface changes or workflow modifications are not evaluated for GxP impact
- No documented re-testing or requalification after significant changes
Why this is weak: Systems drift out of their validated state over time.
What regulators infer: The system may have been validated initially but is no longer demonstrably under control, violating lifecycle expectations in GMP and FDA guidance.
7. Incomplete or Non-Defensible Evidence
Documentation exists but does not withstand inspection scrutiny.
- Missing or unsigned test records, incomplete execution evidence, or absent validation summaries
- Deviations are closed informally without documented root cause, impact assessment, or retesting
- Approval workflows are incomplete or lack clear accountability
Why this is weak: Validation depends on objective evidence. Gaps immediately undermine credibility.
What regulators infer: The validation package is not reliable, and decisions may not have been properly reviewed or justified.
8. Data Integrity Controls Not Verified or Sustained
Data integrity failures increasingly drive inspection findings.
- Audit trails are enabled but not reviewed, or review frequency is undefined
- User access is overly broad, allowing unauthorized data changes
- Records are modified, overwritten, or backdated without traceability
- Raw data and metadata are not consistently retained or reviewed
Why this is weak: Even if validation documentation exists, actual system use does not align with ALCOA+ principles.
What regulators infer: The system cannot ensure data accuracy, completeness, and traceability, creating direct risk to product quality and patient safety.
Failure Pattern Summary
Practical Takeaway
What do inspectors expect from validated systems?
During inspection, regulators do not assess validation as a static document set. They reconstruct a control narrative. They expect to see clear alignment between intended use, risk, testing, and ongoing control, supported by records that demonstrate the system is not only validated once but remains in a validated state.
The key question they are answering is simple: can this system be trusted to support regulated decisions without compromising data integrity or product quality?
1. Clarity of Intended Use and Validation Scope
Inspectors begin by anchoring everything to intended use.
They examine whether the system’s purpose is explicitly defined in terms of:
- regulated process supported, GxP impact, and critical functions affecting quality or patient safety
- clear boundaries of what is in scope versus out of scope, especially in multi-functional or configurable systems
They compare intended use against requirements, risk assessments, and test coverage.
Triggers for concern:
- vague or high-level intended use statements that do not identify critical functions
- scope that shifts across documents or does not match actual system use
- reliance on vendor descriptions instead of firm-defined use
A well-defined intended use allows every downstream decision to be justified. Weak definitions make the entire validation package difficult to defend.
2. Demonstration of Fit-for-Purpose Performance
Inspectors expect objective evidence that the system works as intended in real use.
They review:
- approved requirements and traceability to testing
- executed test protocols with documented results and pass/fail criteria
- final validation report concluding suitability for intended use
They compare test evidence to actual workflows and data handled by the system.
Triggers for concern:
- testing that proves installation but not functional performance in GxP workflows
- missing linkage between requirements and executed tests
- validation conclusions not supported by underlying evidence
An isolated documentation set may appear complete, but if it cannot demonstrate real-world fitness, inspectors will challenge the validity of the system
3. Risk-Based Testing Aligned to Critical Functions
Regulators expect a risk-driven approach consistent with GAMP 5 principles.
They examine whether testing depth matches risk, focusing on:
- functions impacting calculations, data processing, batch disposition, and decision-making
- controls such as audit trails, access management, and data retention
They compare risk assessments with test coverage and execution depth.
Triggers for concern:
- over-testing low-risk features while critical functions receive minimal verification
- lack of rationale for test strategy selection
- absence of challenge testing for high-risk scenarios
A defensible system shows that risks were identified first, then tested proportionally.
4. Data Integrity Controls Embedded in the System
Data integrity is a central inspection focus, especially under 21 CFR Part 11 and global guidance.
Inspectors verify whether the system enforces ALCOA+ principles through design and use:
- records are attributable, contemporaneous, and protected from unauthorized modification
- original data is preserved with no uncontrolled overwriting
- accurate and complete data is consistently maintained
They review system configuration, audit trails, and actual data records.
Triggers for concern:
- ability to overwrite or delete GxP data without traceability
- missing or disabled audit trails for critical data
- backdated entries or inconsistent timestamps
- lack of routine review of data exceptions or anomalies
If integrity controls are weak or inconsistently used, the system may be deemed unreliable regardless of validation documentation.
5. Control of Changes and System Configuration
Inspectors assess whether the validated state is actively protected through change control.
They review:
- records of configuration changes, patches, upgrades, and interface modifications
- impact assessments determining whether revalidation or testing is required
- approval workflows and traceability of implemented changes
They compare system history with documented changes.
Triggers for concern:
- uncontrolled configuration changes or undocumented updates
- changes implemented without impact assessment on data integrity or intended use
- system behavior differing from validated state without explanation
A system is only considered validated if its current state matches its validated configuration.
6. Access Management and Segregation of Duties
Inspectors evaluate whether system access is controlled in line with job responsibilities.
They examine:
- role-based access matrices aligned with user functions
- user account provisioning, modification, and deactivation records
- periodic access reviews and evidence of enforcement
They compare assigned roles against actual user activities.
Triggers for concern:
- shared accounts or generic logins
- excessive privileges such as admin rights assigned without justification
- inactive users retaining access
Weak access control directly undermines data integrity and audit trail reliability.
7. Audit Trails That Are Enabled, Protected, and Reviewed
Inspectors expect audit trails to function as active control mechanisms, not passive features.
They verify that audit trails:
- capture who made changes, what changed, when, and where required why
- cannot be altered or disabled by users
- are reviewed for critical records and exceptions
They compare audit trail entries with actual data changes and workflows.
Triggers for concern:
- audit trails enabled but never reviewed
- incomplete capture of critical events such as data changes or deletions
- inability to reconstruct data history from audit records
An audit trail that exists but is not used is treated as ineffective.
8. Ongoing Review and Proof of a Maintained Validated State
Inspectors do not accept validation as a one-time activity.
They review evidence that the system remains under control through:
- periodic review reports assessing performance, deviations, and changes
- incident trending and evaluation of recurring issues
- backup and restore testing, and verification of data availability
- revalidation or targeted testing following significant changes
They compare historical records to current system performance.
Triggers for concern:
- periodic reviews not performed or performed as a formality without analysis
- recurring incidents without escalation or CAPA
- lack of oversight for vendor-managed or cloud systems
A validated system must show continuous oversight, not assumed control.
Inspection-level takeaway
When can testing be reduced under CSA?
Under FDA’s Computer Software Assurance (CSA) approach, testing can be reduced when a firm can demonstrate that lighter assurance methods still provide sufficient, objective confidence that the system is fit for its intended use without increasing risk to patient safety, product quality, or process performance. This is a risk-based decision, not a simplification exercise. The burden shifts from executing scripted tests to justifying why the chosen level of assurance is appropriate and defensible.
Decision criteria
1. Impact on patient, product, and process risk
The primary decision driver is the functional risk of failure.
- Testing can be reduced when failure of the function would not reasonably impact patient safety, product quality, or critical process performance
- Low-risk examples include UI formatting, reporting layouts, non-GxP workflow routing, or informational dashboards without decision-making impact
- The decision becomes weak when firms label functions as “low risk” without analyzing downstream effects such as indirect impact on batch decisions or data interpretation
- Any function tied to batch disposition, critical calculations, or quality decisions requires stronger, often scripted, verification
A defensible position shows a clear failure mode analysis, not just a generic risk label.
2. Clarity and limitation of intended use
CSA allows reduced testing when the GxP-relevant scope is tightly defined.
- Testing can be reduced when the intended use is narrow and only a subset of system functionality is GxP-relevant
- Example: a LIMS module used only for sample login tracking versus full analytical result processing
- Weak decisions occur when intended use is vaguely defined, allowing uncontrolled expansion of system reliance without corresponding assurance
- Inspectors expect traceability from intended use to tested functionality, not blanket validation of the entire system
If intended use is unclear, reduced testing is not defensible.
3. Software maturity and supplier evidence
Reliance on supplier validation is a key CSA enabler, but only when justified.
- Testing can be reduced when the software is commercially mature, widely used, and supported by credible supplier documentation such as development testing, release notes, and quality certifications
- Example: standard ERP or cloud platform features with established vendor validation packages
- The decision is weak when supplier evidence is accepted without critical review, or when configuration/customization introduces new risks not covered by the supplier
- High customization or bespoke code invalidates most supplier reliance and requires deeper testing
Regulators expect firms to evaluate supplier evidence, not inherit it blindly.
4. Suitability of unscripted or exploratory testing
CSA explicitly supports replacing scripted testing with more efficient approaches where appropriate.
- Testing can be reduced when exploratory, scenario-based, or unscripted testing can effectively challenge the function
- Example: user-driven workflows, usability checks, or configuration verification where rigid scripts add no value
- Weak execution occurs when unscripted testing is undocumented, lacks defined objectives, or fails to capture observed outcomes and defects
- Exploratory testing must still produce objective evidence, including what was tested, what issues were found, and how they were resolved
The method can be lighter, but the evidence must remain credible and reviewable.
5. Proportionality of documentation and test effort
CSA allows reduction of documentation burden when it does not add value.
- Testing can be reduced when extensive scripted protocols, step-by-step evidence, or repetitive regression testing do not meaningfully increase assurance relative to the function’s risk
- Example: eliminating redundant test scripts for stable, low-risk features across releases
- Weak decisions occur when documentation is reduced without preserving rationale, resulting in gaps in traceability or justification
- Inspectors expect clear records explaining why a lighter approach was chosen and how it still demonstrates fitness for use
The expectation is “less volume, same or better clarity.”
6. Strength of the risk-based rationale chain
Regulators evaluate the logic connecting risk to assurance depth.
- Testing can be reduced when the firm can clearly demonstrate: intended use → risk classification → chosen test method → resulting evidence
- A defensible decision answers: what can fail, how severe is the impact, what evidence exists, and why the selected testing is sufficient
- Weak decisions rely on templates or policy statements without linking them to specific system functions
- Inconsistent application across similar systems is a common inspection finding
The decision must be traceable and consistent, not subjective.
When the wrong decision creates compliance risk
Reducing testing inappropriately typically fails in predictable ways:
- Critical calculations are lightly tested, leading to incorrect potency or yield results used in batch release decisions
- Audit trail functionality is inadequately verified, resulting in undetected data changes or missing traceability under 21 CFR Part 11
- Access controls are insufficiently tested, allowing unauthorized data modification or privilege escalation
- Supplier evidence is accepted without confirming version alignment, leaving gaps between tested and deployed configurations
- Exploratory testing is performed but not documented, creating a lack of objective evidence during inspection
- Intended use is expanded post-validation without reassessing risk, invalidating the original testing strategy
These failures are not about lack of testing volume. They stem from weak justification and poor linkage between risk and assurance.
Practical takeaway
A defensible CSA decision to reduce testing follows a structured evaluation:
- Define intended use precisely and limit the GxP scope
- Assess functional risk based on real failure impact, not system category
- Identify existing evidence including supplier documentation and prior validation
- Select the least burdensome testing method that can still challenge the function effectively
- Document the rationale clearly, including why additional testing would not improve assurance
- Ensure all high-impact controls such as calculations, audit trails, electronic records, and access control remain rigorously tested
Reduced testing under CSA is justified only when it is demonstrably sufficient. The regulator’s focus is not how much testing was done, but whether the chosen approach reliably assures that the system performs as required in a GxP environment.
What documentation is required for system validation?
Validation documentation for a GxP computerized system must demonstrate a complete, traceable lifecycle from intended use through risk-based verification to controlled operation. Under both traditional Computer System Validation (CSV) and modern Computer Software Assurance (CSA), regulators expect a focused but complete set of records that prove the system is fit for purpose and remains in a validated state. The emphasis is not on document volume, but on whether the documentation shows a clear, defensible thread linking requirements, risk, testing, and ongoing control.
Core Required Records
1. Validation Planning and Intended Use
- Validation or assurance plan defines scope, system boundaries, roles and responsibilities, deliverables, acceptance criteria, and the chosen validation approach, including justification for risk-based methods under CSA
- Intended use statement clearly identifies GxP-relevant functions, data flows, interfaces, and system limitations so validation effort is focused on what impacts product quality, patient safety, or data integrity
Weak execution here often results in validation packages that test everything superficially but fail to justify why certain functions matter.
2. Requirements and Risk Definition
- User requirements or system requirements must be specific, testable, and unambiguous, with direct linkage to GxP processes such as batch release, laboratory data handling, or electronic records management
- Risk assessment evaluates potential failure modes, severity, and likelihood, and explicitly justifies the depth and type of testing performed, including where unscripted or exploratory testing is acceptable under CSA
- Supplier assessment documents vendor qualification, quality system maturity, and clearly defines which validation activities are performed by the supplier versus the regulated company
Inspectors expect alignment between these elements. A common failure is generic requirements copied from vendor templates with no linkage to actual process risk, leading to either over-testing low-risk features or under-testing critical ones.
3. Test and Verification Evidence
- Test protocols or assurance activities define how requirements and risks are verified, with scripted testing for high-risk functions and flexible approaches for lower-risk areas where justified
- Executed test evidence includes raw outputs such as system logs, screenshots, data comparisons, and reviewer sign-offs demonstrating that tests were actually performed and evaluated
- Traceability matrix links requirements to risks, controls, test cases, and outcomes, providing a single view of coverage and gaps
- Deviation or defect records document failures during testing, including impact assessment on product quality or data integrity, root cause, resolution, and evidence of retesting where required
What matters is objective evidence. Inspectors routinely reject test documentation that only shows “pass” statements without supporting data or that lacks traceability back to requirements.
4. Release and Lifecycle Control
- Validation summary report provides a consolidated conclusion on whether the system meets its intended use, summarizes deviations, and justifies any residual risks accepted at release
- Approval and sign-off records demonstrate that quality, system owners, and business stakeholders formally authorized the system for GxP use
- Change control records capture post-validation changes such as configuration updates, patches, upgrades, and interface modifications, including risk assessment and revalidation decisions
- Operational SOPs and periodic review records define how the validated state is maintained, including procedures for access control, audit trail review, backup and restore, incident management, and periodic evaluation of system performance
A validated system without lifecycle controls is considered out of compliance. Inspectors look for evidence that validation is not a one-time event but an ongoing state of control.
What Weak Documentation Looks Like
- Requirements that are vague, non-testable, or copied from vendor documentation without alignment to actual GxP use
- Risk assessments that are superficial, missing severity justification, or not used to drive testing strategy
- Test records that show only summary results without raw data, screenshots, or logs to support conclusions
- Traceability gaps where requirements, risks, and tests cannot be clearly linked
- Deviations documented without impact assessment or without evidence of resolution and retesting
- Validation reports that simply restate activities without making a clear fitness-for-use decision
- Change control records that do not assess validation impact or fail to trigger revalidation when required
- Supplier documentation included as-is without mapping to system configuration, intended use, and site-specific risks
Excess documentation is also a problem. Large volumes of duplicated protocols, unnecessary printouts, or generic validation binders dilute the actual evidence and make it harder to demonstrate control.
Data Integrity Implications
For systems managing electronic records under regulations such as 21 CFR Part 11 or EU Annex 11, validation documentation must also support data integrity controls:
- Evidence that audit trails are enabled, reviewed, and linked to critical data changes
- Documentation of role-based access controls, including prevention of unauthorized data modification or deletion
- Test evidence showing data cannot be overwritten without traceability, including failed attempts and system responses
- Records demonstrating backup and restore processes preserve complete and accurate data
- Change control and configuration records that prevent uncontrolled system changes impacting data integrity
Common inspection findings include missing audit trail reviews, shared user accounts, and lack of testing around data modification controls. These directly undermine ALCOA+ principles and can invalidate the entire validation effort.
Practical Takeaway
Inspection-ready validation documentation is defined by coherence, not volume. The critical expectation is a clear, defensible chain:
- intended use defines what matters
- requirements translate that use into testable expectations
- risk assessment determines how deeply each function is tested
- test evidence proves those expectations are met
- deviations and decisions are documented transparently
- summary and approvals confirm fitness for use
- change control and SOPs ensure the system stays in control
If this chain is complete and traceable, the documentation can be lean and still withstand inspection. If the chain is broken, no amount of additional paperwork compensates for the gap.
Copyright © 2026
